CLEVELAND, June 26, 2017 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the National Cancer Center
(NCC) in Tokyo, Japan treated its
first patients using ViewRay's MRIdian System, the world's first
and only clinical MRI-guided radiation therapy system. Among the
first indications treated at NCC were cancers of the lung, liver
and pancreas.
The MRIdian System combines MR imaging with radiation delivery
so clinicians can visualize soft tissue and adjust their dosing —
all in real-time, on live anatomy. With MRIdian this is done
without exposing the patient to the additional ionizing radiation
that is common with other imaging modalities.
"We're pleased to have commenced patient treatments with our
MRIdian System and are already seeing firsthand the benefits of
combining MRI with radiation delivery and the value of adapting our
plan during treatment to account for motion and changes in the
tumor and nearby anatomy," said Jun Itami, M.D., Ph.D., chair
of the Department of Radiation Oncology, NCC. "MRIdian will allow
us to expand the number and types of cancer patients we treat,
including some patients who may have been considered untreatable
previously with conventional radiation therapy."
The National Cancer Center Japan has been providing patient care
for more than 50 years. The NCC is at the forefront of research in
cancer treatment and plays a central role in training doctors,
nurses and other medical professionals to specialize in cancer
medicine.
"It's exciting to have the first MRIdian treatments in
Japan underway at the NCC," said
Chris A. Raanes, president and chief
executive officer of ViewRay. "MRIdian offers significant
advantages in its real-time soft-tissue tracking and on-table
adaptive delivery, and we're pleased that patients in Japan are now experiencing the benefits of
this important advance in cancer care."
ViewRay received Shonin approval from the Japanese Ministry of
Health, Labor and Welfare (MHLW) in August
2016 to market the Cobalt-based MRIdian System within
Japan. ViewRay is represented in
Japan by ITOCHU Corporation, one
of the three largest general trading companies in Japan. ITOCHU has been focusing on the
healthcare business to promote important medical innovations in
Japan for approximately 40
years.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy system.
MRIdian integrates MRI technology, radiation delivery and
proprietary software to locate, target and track the position and
shape of soft-tissue tumors during radiation. ViewRay believes this
combination of enhanced visualization and accuracy will
significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay,
Inc.
Forward Looking Statements:
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to the benefits of the
MRIdian System for physicians and patients in Japan and the first patient treatments by the
NCC. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
These forward-looking statements are made as of the date of this
press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should consult all
of the information set forth herein and should also refer to the
risk factor disclosure set forth in the reports and other documents
ViewRay files with the SEC available at www.sec.gov.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/national-cancer-center-japan-treats-first-patients-using-viewray-mridian-system-300479376.html
SOURCE ViewRay, Inc.